Ridge Diagnostics wins Phase II National Science Foundation grant

Ridge Diagnostics, a neurodiagnostic company commercializing a proprietary blood test for depression or major depressive disorder, has received a Phase II, National Science Foundation, Small Business Innovation Research program grant.

According to the company, the grant will be used to further the clinical development and commercialization of the company’s blood test for depression, reported to be the first blood test for any neuropsychiatric disorder.

The test can be used in pharmaceutical research to objectively identify and stratify patient populations to enhance drug research and clinical studies, the company said. It is intended to be used by psychiatrists and primary care physicians to diagnose and monitor treatment of patients with depression.

Stan Sewitch, president and CEO of Ridge, said: We are pleased to announce the National Science Foundation’s recognition of Ridge’s technological accomplishments. This grant will enable us to further the clinical development of our blood tests and build on our Clinical Laboratory Improvement Amendments laboratory infrastructure to support our growing business.

Ridge Diagnostics is a neurodiagnostic company commercializing a breakthrough, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company’s products are derived from a proprietary Human Biomarker Library and Hyper-MappingTM technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic franchise.